MedTrace Logo

Intranasal Dexmedetomidine Versus Intranasal Midazolam for MRI In Pediatrics

NCT04652661 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-20

No results posted yet for this study

Summary

An increasing number of studies have reported the use of dexmedetomidine in clinical practice. However, few studies have reported on the intranasal use of dexmedetomidine in radiological procedures The aim of this work is to compare the efficacy and safety of intranasal dexmedetomidine and intranasal midazolam in pediatrics undergoing MRI.

Conditions

  • Dexmedetomidine
  • Midazolam
  • MRI
  • Pediatrics

Interventions

DRUG

Dexmedetomidine

30 children will be sedated with 2 μg/kg intranasal DEX.

DRUG

Midazolam

30 children will be sedated with 0.3 mg/kg intranasal midazolam.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2022-01-01
Completion
2022-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652661 on ClinicalTrials.gov